Literature DB >> 28304141

Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review.

Martin L Kårhus1, Andreas Brønden1, David P Sonne1,2, Tina Vilsbøll1,3,4, Fillip K Knop1,3,5.   

Abstract

Bile acids are amphipathic water-soluble steroid-based molecules best known for their important lipid-solubilizing role in the assimilation of fat. Recently, bile acids have emerged as metabolic integrators with glucose-lowering potential. Among a variety of gluco-metabolic effects, bile acids have been demonstrated to modulate the secretion of the gut-derived incretin hormone glucagon-like peptide-1 (GLP-1), possibly via the transmembrane receptor Takeda G-protein-coupled receptor 5 and the nuclear farnesoid X receptor, in intestinal L cells. The present article critically reviews current evidence connecting established glucose-lowering drugs to bile acid-induced GLP-1 secretion, and discusses whether bile acid-induced GLP-1 secretion may constitute a new basis for understanding how metformin, inhibitors of the apical sodium-dependent bile acids transporter, and bile acid sequestrants - old, new and neglected glucose-lowering drugs - improve glucose metabolism.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990GLP-1; ASBT inhibitors, bile acid, bile acid sequestrants, drug mechanism; antidiabetic drug; incretin therapy; metformin; type 2 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28304141     DOI: 10.1111/dom.12946

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  7 in total

1.  Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus.

Authors:  Petter Bjornstad; Michal Schäfer; Uyen Truong; Melanie Cree-Green; Laura Pyle; Amy Baumgartner; Yesenia Garcia Reyes; Aristides Maniatis; Sunil Nayak; R Paul Wadwa; Lorna P Browne; Jane E B Reusch; Kristen J Nadeau
Journal:  Circulation       Date:  2018-12-18       Impact factor: 29.690

2.  Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study.

Authors:  Takeshi Osonoi; Miyoko Saito; Naoya Koda; Satako Douguchi; Takako Nakano; Kensuke Ofuchi; Makoto Katoh
Journal:  Diabetes Metab Syndr Obes       Date:  2020-10-05       Impact factor: 3.168

Review 3.  Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases.

Authors:  Baoyi Guan; Jinlin Tong; Haiping Hao; Zhixu Yang; Keji Chen; Hao Xu; Anlu Wang
Journal:  Acta Pharm Sin B       Date:  2021-12-22       Impact factor: 14.903

4.  Bile acid signaling and bariatric surgery.

Authors:  Jingyan Tian; Silvia Huang; Siming Sun; Lili Ding; Eryun Zhang; Wendong Huang
Journal:  Liver Res       Date:  2017-12

5.  Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015.

Authors:  Matthew J Crowley; Mugdha Gokhale; Virginia Pate; Til Stürmer; John B Buse
Journal:  Diabetes Obes Metab       Date:  2018-12-18       Impact factor: 6.408

6.  The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study.

Authors:  Boyu Li; Yanjin Hu; Guang Wang; Lihong Liu
Journal:  BMC Pharmacol Toxicol       Date:  2020-06-15       Impact factor: 2.483

Review 7.  Role of Bile Acids in the Regulation of Food Intake, and Their Dysregulation in Metabolic Disease.

Authors:  Cong Xie; Weikun Huang; Richard L Young; Karen L Jones; Michael Horowitz; Christopher K Rayner; Tongzhi Wu
Journal:  Nutrients       Date:  2021-03-28       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.